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Sphingolipid (SL) de novo synthesis typically starts with 
the condensation of serine and palmitoyl-CoA, a reaction 
catalyzed by serine palmitoyltransferase (SPT) (1–3). SPT 
can also use alanine in certain conditions (4), which results 
in the formation of the atypical cytotoxic 1-deoxysphingo-
lipids (1-deoxySLs). These lack the C1-hydroxyl group of 
regular SLs, which is essential for further metabolic steps 
and degradation (4, 5). As such, 1-deoxySLs are commonly 
believed to be “dead-end” metabolites that accumulate 
within cells, tissues, and body fluids.
Pathologically elevated 1-deoxySLs have been found in a 
number of neurological and metabolic disorders. They are 
a hallmark of hereditary sensory autonomic neuropathy 
type 1 (HSAN1), a rare autosomal dominant inherited pe-
ripheral neuropathy that is caused by various mutations in 
SPT. Plasma 1-deoxySLs are also elevated in patients with 
nondiabetic metabolic syndrome (MetS) and T2D (6) and 
may contribute to the development of diabetic sensory 
polyneuropathy (DSN), which is clinically very similar to 
HSAN1 (7, 8). Both conditions start in the lower extremi-
ties with a loss of sensation often accompanied by positive 
sensory symptoms such as hyperpathia and neuropathic 
pain, as well as the development of painless wounds lead-
ing to ulcers (9, 10). L-serine supplementation was shown 
to effectively lower 1-deoxySL levels while improving 
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3, 4, 6, and 8 days for the long-term chase experiments. For the 
experiments with HET0016, the inhibitor was present in the me-
dium throughout the entire duration of both the pulse and chase 
periods. Cells were harvested at the time points specified above by 
first washing with PBS, followed by trypsinization in 500 l for 
3 min. An equal volume of growth medium was added to stop 
trypsinization and cells were counted (Z2 Coulter Counter; Beck-
man Coulter, Brea, CA) and pelleted (800 g, 5 min at 4°C). The 
cell pellet was subsequently resuspended in 1 ml cold PBS and 
centrifuged, and PBS was removed by aspiration.
The pulse medium was collected upon exchanging with un-
supplemented growth medium. Before harvesting the cells, the 
chase medium from all the time points was also collected, lyophi-
lized overnight (Christ Alpha 2-4 LSC Freeze Dryer; Kuhne, Birs-
felden, Switzerland), and stored at 20°C until extraction of the 
SLs.
For the metabolic order assay, MEF cells were treated with 
1 M of either d3-deoxySA-OH, d3-deoxySO-OH, d3-deoxySA, or 
three synthetic 1-deoxySO analogs with different DB positions 
(4,5-trans; 14,15-trans; and 14,15-cis). Cells were harvested after 48 h.
For  the  CYPA/CYP4F  inhibition  and  induction  assays,  MEF 
cells treated with 1 M d3-deoxySA alone or in combination with 
HET0016 (5 M; Santa Cruz Biotechnology), fenofibrate (20 M; 
Sigma), or retinoic acid (20 M, Sigma), respectively, and harvested 
after 24 h. For the downstream metabolite inhibition curves with 
HET0016, MEF cells were treated with 1 M d3-deoxySA and the 
following concentrations of the inhibitor for 24 h: 50 nM, 100 nM, 
500 nM, 1 M, 2.5 M, 5 M, and10 M.
HEK-WT, HEK-Cyp4a10, and HEK-Cyp4f13 cells were treated 
with 1 M d3-deoxySA. After 48 h, cells were washed with 2 ml 
PBS and then harvested in 1 ml PBS, counted, and pelleted (800 g, 
5 min at 4°C).
Please note that for the pulse-chase experiments, units are in 
total picomoles to account for the dilution of the labeled lipids 
taken up in the pulse period by the multiplication of cells, while 
for the steady state experiments, units are in picomoles per 1e6 cells.
Extraction and analysis of sphingoid and deoxysphingoid 
bases
The frozen cell pellets were resuspended in 100 l PBS and the 
lyophilized medium was also dissolved in 100 l of PBS prior to 
extraction. Five hundred microliters of methanol (Honeywell), 
including 200 pmol of internal standard [d7-sphinganine (d7-SA) 
and d7-sphingosine (d7-SO); Avanti Polar Lipids] was added to 
each sample. Lipids were extracted by shaking in a Thermomixer 
for 1 h at 1,000 rpm and 37°C (Thermomixer Comfort; Eppen-
dorf, Hamburg, Germany). To pellet precipitated protein, sam-
ples were centrifuged at 16,000 g for 5 min and the supernatant 
was transferred to a new tube. Lipids were acid/base hydrolyzed 
to remove the N-acyl chain, as described earlier (4, 23).
Before  analysis  by  LC/MS,  lipids  were  redissolved  in  75  l 
of 56.7% methanol, 33.3% ethanol, 10% water, and derivatized 
with 5 l OPA working solution [990 l boric acid (3%) + 10 l 
o-phthalaldehyde (50 mg/ml in ethanol) + 0.5 l 2-mercaptoeth-
anol]. OPA was used for derivatization in order to improve the 
chromatographic separation of peaks and also to aid with the 
specificity of the metabolite search later on, as only SL metabo-
lites with an amino group would be derivatized.
The hydrolyzed sphingoid bases were separated on a C18 col-
umn (Uptispere 120 Å, 5 m, 125 × 2 mm; Interchim, Montluçon, 
France) using a Transcend UPLC pump (Thermo, Reinach, BL, 
Switzerland) at  a flow  rate of 0.3 ml/min with a binary  solvent 
system,  where  solvent  A  was  1:1  methanol/ammonium  acetate  
(5 mM) in water, and solvent B was methanol. The column was 
first equilibrated using a mixture of 50% mobile phase A and 50% 
mobile phase B, and then 25 l of sample was injected, which was 
neuropathic symptoms in a HSAN1 mouse model as well as 
in a diabetic rat model (11, 12). In addition, 1-deoxySLs 
were shown to be elevated under Taxol treatment and 
might contribute to Taxol-induced peripheral neuropathy 
(13). Furthermore, 1-deoxySLs were found to be increased 
in patients with nonalcoholic steatohepatitis (14) and to 
interfere with the function and survival of pancreatic -
cells (15). Elevated 1-deoxySL plasma levels are also predic-
tive for the risk to develop T2D (6).
The 1-deoxysphinganine (1-deoxySA), which is formed 
by SPT through the condensation of palmitoyl-CoA and 
alanine, is N-acylated to 1-deoxy-dihydroceramides (5, 16, 
17). However, while canonical dihydroceramides are con-
verted to ceramides by the introduction of a 4,5 trans 
double bond (DB) (18, 19), a 14,15 cis DB is most com-
monly introduced in 1-deoxy-dihydroceramides (20), indi-
cating that 1-deoxySLs follow a different metabolic route 
than canonical SLs. Upon degradation, ceramides are typi-
cally hydrolyzed to sphingosine (SO), and then converted 
to the catabolic intermediate, sphingosine-1-phosphate 
(S1P) (21), which is irreversibly degraded by S1P lyase (22). 
This is not possible for 1-deoxysphingosine (1-deoxySO), 
as the C1-hydroxyl group is missing.
In this work, we addressed the issue of 1-deoxySL me-
tabolism and degradation in more detail. We demonstrated 
for the first time that 1-deoxySO is metabolized to a variety 
of downstream metabolites through reactions that are at 
least partly mediated by enzymes of the cytochrome P450 
(CYP)4F subfamily.
MATERIALS AND METHODS
Cell culture
Mouse embryonic fibroblasts (MEFs) were grown and main-
tained in DMEM (Sigma) with 10% FBS (Fisher Scientific; FSA15-
043),  and  1%  penicillin/streptomycin  (P/S;  100  units  per 
milliliter/0.1 mg per milliliter; Sigma) at 37°C and 5% CO2.
Transfection of Cyp4a10, Cyp4f13 in HEK cells
HEK293 cells were grown in DMEM + 10% FBS + 1% P/S. Four 
micrograms of the Cyp4a10 and Cyp4f13 plasmids (Origene, Rock-
ville, MD) were diluted in 400 l of Opti-MEM I (Gibco; 51985) 
and then gently vortexed. Eight microliters of TurboFect transfec-
tion reagent (ThermoFisher) were added to the diluted DNA, 
mixed by gently pipetting, and incubated for 20 min at room tem-
perature.  The  TurboFect/DNA mixture  was  then  added  drop-
wise to the cells. Forty-eight hours after transfection, the cells were 
split at a 1:10 dilution into 10 ml of growth medium plus 400 
g/l Geneticin (Gibco) for selection and passaged three times 
before being used for experiments. Expression of the CYP4A10 
and CYP4F13 proteins was confirmed by Western blot using a rab-
bit anti-FLAG-tag antibody (Serotec).
Metabolic labeling assays
Deuterated and unlabeled 1-deoxySL 1 mM stock solutions 
were prepared by dissolving the lipids in 100% ethanol (Sigma).
For the pulse-chase experiments, MEF cells were treated with 
1 M deuterium-labeled (d3) 1-deoxySA or d7-SA (Avanti Polar 
Lipids) for 2 h, after which they were chased for 0, 1, 4, 8, 24, and 
48 h with unsupplemented growth medium (DMEM), or for 1, 2, 
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The 1-deoxySLs with mass offsets of +6, +5, +4, +3, +2, +1, as well 
as the unlabeled mass M were quantified in order to account for 
the natural isotopologues, as well as the +3 labeling arising from 
the d3-palmitic acid or the d4-alanine (one deuterium is lost 
from the alanine upon condensation with the palmitoyl-CoA) 
and the +6 labeling arising from the condensation of both la-
beled substrates.
LC fraction separation
Pure amounts of some of the newly identified 1-deoxySL 
metabolites were obtained by fractionating the LC eluate at the 
specific retention times of the metabolites. Each fraction was col-
lected by using a divert valve after the LC column. The fractions 
were eluted in 50% methanol and 50% 1:1 methanol/ammonium 
acetate. The mobile phase was evaporated under a steady stream 
of nitrogen (Techne Sample Concentrator; Bibby Scientific Ltd., 
Staffordshire, UK). In order to remove the ammonium acetate 
from the separated fractions, the lipids were extracted by redissolv-
ing in 100 l PBS + 666 l methanol + 333 l chloroform. The sam-
ples were then agitated at 1,000 rpm 37°C for 1 h (Thermomixer 
Comfort; Eppendorf), followed by the addition of 500 l chloro-
form and 200 l of alkaline water. The upper (water) phase was 
removed by aspiration, and the lower (organic) phase was washed 
three times with 1 ml of alkaline water. Lipids were dried under a 
steady stream of nitrogen and resuspended in ethanol. Fraction 
purity and concentration were measured by spiking with internal 
standards (d7-SA and d7-SO) and running on the LC/MS as de-
scribed above. There was less than 1% contamination with any of 
the other d3-deoxySL metabolites in the purified d3-deoxySO-OH 
fraction and 5% contamination in the d3-deoxySA-OH fraction 
with d3-deoxySO-OH.
Statistical analysis
Statistical significance was calculated by a two-tailed Student’s 
t-test and ANOVA using GraphPad Prism 6.
RESULTS
The decrease in intracellular d3-deoxySA over time is not 
compensated for by the increase in d3-deoxySO
To examine whether 1-deoxySO is the end product of 
1-deoxySL metabolism, we supplemented cells with a pulse 
of the isotope-labeled precursor d3-deoxySA (2 h) followed 
by a chase with unsupplemented growth medium. Lipids 
were extracted and acid/base hydrolyzed to remove the N-acyl 
chain, and the d3-deoxysphingoid bases were quantified by 
LC/MS. We  observed  a  time-dependent  decrease  of  d3-
deoxySA within 48 h to approximately half of the initial 
concentration (Fig. 1A). However, this decrease was not 
compensated for by an equivalent increase in the down-
stream product d3-deoxySO. In fact, d3-deoxySO increased 
only for the first 24 h, and then started to decline again 
(Fig. 1A). At 48 h, the sum of d3-deoxySA and d3-deoxySO 
was less than half of what was measured directly after the 
pulse (Fig. 1B). The total levels of d3-labeled deoxysphin-
goid bases (d3-deoxySA + d3-deoxySO) in the medium 
were constant over time (Fig. 1C).
One explanation for this loss in labeled d3-deoxySLs 
could be the conversion to canonical C18-SLs by a hydrox-
ylation/oxygenation  at  C1.  The  addition  of  a  hydroxyl 
group at C1 would result in the replacement of one of the 
eluted by the same mixture for 1 min. This was followed by a ramp 
gradient over 25 min to 100% phase B, which remained until 32 
min, followed by a ramp gradient back down to 50% solvent A and 
50% solvent B for 1 min, and column equilibration with the same 
mixture for 2 min. The sphingoid and deoxysphingoid bases were 
ionized using an atmospheric pressure chemical ionization source 
and detected on a Q-Exactive hybrid quadrupole Orbitrap mass 
spectrometer (Thermo). The detection was performed in full 
scan mode, with a scan range of m/z 120–1,200, mass resolution of 
140,000, automatic gain control target 3.00E+06, and maximum 
injection time of 512 ms.
Differential analysis
The software Sieve 2.0 (ThermoFisher) was used to perform 
differential analysis of the lipidomics dataset obtained for the dif-
ferent time points of the pulse-chase experiments. The basic 
workflow used to perform the differential analysis was described 
by Snyder et al. (24). The software aligns the retention times of 
the chromatographic peaks between the two conditions being 
compared, after which it defines frames based on retention time, 
mass, and intensity (i.e., the area under the peak), where each 
frame represents an individual metabolite, its isotopes, or any 
fragment measured. A list of 486 frames was populated from the 
comparison of time points 0 and 48 h of the chase, translating 
into approximately 312 components after filtering out natural iso-
topologues. The software calculated a ratio of the change in levels 
between the two conditions compared, and also the statistical sig-
nificance of the change, as triplicate measurements were used. All 
frames were normalized to the spiked internal standard d7-SA.
The components that were classified as changing between the 
time points were then filtered based on the following criteria: 400 < 
m/z < 510, as that is the mass range of OPA-derivatized sphingoid 
bases; a retention time <26 min, as that is when the washing of the 
column begins; a ratio >1, as this would indicate a change between 
the two time points; and a P value <0.05. We further filtered the 
components by selecting for lipid metabolites with odd-numbered 
masses because these would be expected to contain the d3 label. 
Because samples were derivatized with o-phthalaldehyde (OPA) 
before running on the MS, we applied the added criteria that the 
molecular formula should contain one sulfur, which comes from 
the OPA working solution. We then generated the molecular for-
mula from the accurate mass (within 5 ppm) of the remaining 
compounds after all restrictions were applied.
Visual analysis of the total ion chromatogram
To ensure that no metabolites were excluded by the Sieve soft-
ware due to low levels or incomplete peak separation at baseline, 
the total ion current plot was analyzed scan by scan over the dura-
tion of each run (35 min), using the same restrictions as above 
(i.e., odd-numbered mass, the accurate mass of the compound 
should be able to generate a formula containing one sulfur). We 
analyzed the mass spectra of each scan in the total ion current 
plot for the most intense m/z present in order to identify new me-
tabolites containing the d3 label.
Deuterium exchange assay with deuterium-labeled 
substrates
MEF cells overexpressing the SPT enzyme with the mutation 
SPTLC1-C133W, which were obtained from Vincent Timmerman 
(University of Antwerp, Belgium), were grown in DMEM with 
10% FBS, 1% P/S, and 4 g/ml Geneticin. The cells were treated 
with methyl-d3 palmitic acid (Cambridge Isotopes) as a 1:1 molar 
complex with fatty acid-free BSA, as well as with d4-alanine (Cam-
bridge Isotopes), and harvested after 48 h. SLs were extracted and 
acid/base  hydrolyzed  as  described  and  measured  by  LC/MS.  
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compared with the canonical unlabeled lipids. The incor-
poration of the label into canonical SA or SO would result 
in  an  altered  (M+2)/M  or  (M+3)/M  ratio.  However,  as 
there was no change in the relative amounts of M+2 and 
M+3 between the 0 and 48 h time points, nor when com-
pared with untreated cells (Fig. 1D), this indicates that 
there was no conversion of the 1-deoxySLs to canonical 
SLs.
Eight novel 1-deoxySLs identified increase over time
Next, we systemically screened for unknown labeled 
1-deoxySL downstream metabolites that changed between 
the 0 and 48 h time points. We used the metabolic profiling 
software “Sieve” to perform differential analysis of the mass 
spectra. This identified 312 components that showed sig-
nificant differences. Of them, 56 remained valid after ap-
plying further filtering criteria, as described in the Materials 
deuteriums, which would therefore result in a d2-labeled 
C18 sphingoid base. Alternatively, an oxygen could also be 
added to C1 by nucleophilic attack, as occurs through the 
action of heme-dependent mono-oxygenases (see supple-
mental Fig. S1 for a depiction of the two reactions). In this 
case there would be no deuterium loss, and the resulting 
SA and SO bases would have a d3 label (see supplemental 
Fig. S1 for a depiction of the two different reactions). As 
most elements occur as a mixture of isotopes, this results in 
compounds having different isotopologues whose relative 
amounts are based on the occurrence of the atomic iso-
topes in nature. Here, we refer to the mass of the canonical 
SA/SO as M, where M+2 and M+3 are usually the natural 
isotopologues having two or three 13C atoms, respectively. 
However, in this case, we have also used them to refer to 
the potential d2- and d3-labeled SA and SO, as these labels 
would also result in a mass of +2 and +3, respectively, when 
Fig. 1. Total levels of d3-labeled 1-deoxySLs decrease over a 48 h chase period. A: MEFs were treated with a 2 h pulse of d3-deoxySA fol-
lowed by a chase with unsupplemented growth medium; time point 0 represents the start of the chase period. The levels of d3-deoxySA de-
creased over the duration of the chase, while d3-deoxySO increased up to 24 h and then also decreased (after acid/base hydrolysis). Inlay is 
a magnified version of the d3-deoxySO levels over time. Statistical significance for the difference in the levels of d3-deoxySA and d3-deoxySO 
at each time point when compared with time point 0 was calculated using a one-way ANOVA with a Bonferroni correction for comparing 
selected pairs. B: Total d3-deoxySA + d3-deoxySO levels decreased by a factor of 2 between the 0 and 48 h time points of the chase. C: The 
growth medium was collected at all time points of the chase and the lipids were extracted. The total levels of d3-labeled deoxysphingoid bases 
(d3-deoxySA + d3-deoxySO) in the medium did not change over time. D: The ratio of (M+2)/M and (M+3)/M SA and SO, where M is the 
mass of the canonical unlabeled sphingoid bases, were unchanged between the 0 and 48 h time points of the chase, as well as when compared 
with untreated control cells. Points and bars represent averages ± SEM. Statistical significance was calculated using a one-way ANOVA fol-
lowed by Bonferroni correction. **P < 0.01, ****P < 0.0001; n.s., not significant.
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sphingoid bases compared with the d3-labeled deoxysphin-
goid bases was about 80% lower at the beginning of the 
chase (t = 0 h) (Fig. 3A). This indicates that a great propor-
tion of the supplemented d7-SA was already metabolized 
within the 2 h of the pulse.
To determine whether the newly identified 1-deoxySL 
downstream metabolites are converted further, we per-
formed an extended pulse-chase experiment over a period 
of 8 days. During this long-term chase, the newly identified 
downstream metabolites increased within the first 4–6 days 
and then declined again (Fig. 3B).
The novel metabolites are all downstream of 1-deoxySO 
and form a branched pathway
As demonstrated recently, the 1-deoxySO that is the 
most abundant in a variety of cell types as well as in human 
plasma bears a 14,15-cis DB in contrast to the 4,5-trans 
DB of canonical sphingosine (20). To elucidate the order 
in which the newly identified metabolites are formed and 
to determine where they integrate into the 1-deoxySL met-
abolic pathway, we treated MEF cells for 48 h with either 
d3-deoxySA, native 14,15-cis-deoxySO, or two synthetic 
1-deoxySO isomers (4,5-trans and 14,15-trans). For d3-
deoxySA-treated cells, the d3-labeled metabolites were 
quantified, while in the 1-deoxySO-treated cells, the unla-
beled  metabolites  were  quantified  (after  acid/base  hy-
drolysis). The levels of 1-deoxySAdiene, 1-deoxySA-OH, 
1-deoxySO-OH, and 1-deoxySA-2OH all significantly in-
creased after adding 14,15-cis-deoxySO, indicating that all 
of these metabolites are formed downstream of 1-deoxySO 
(Fig. 4A). Also, treatment with the synthetic isomers 4,5-
trans-deoxySO and 14,15-trans-deoxySO significantly in-
creased the levels of all downstream metabolites, suggesting 
that the responsible enzymes are not very substrate spe-
cific (Fig. 4A). However, the relative proportion of the 
formed downstream metabolites differed between treat-
ments. Cells treated with 4,5-trans-deoxySO formed ap-
proximately 10-fold more 1-deoxySAdiene compared with 
cells treated with d3-deoxySA, 14,15-trans-deoxySO, or 
14,15-cis-deoxySO (Fig. 4A).
In addition, we supplemented cells with native d3-de-
oxySA-OH and d3-deoxySO-OH (I + II), isolated by LC 
fractionation after a prolonged treatment with d3-deoxySA. 
The addition of d3-deoxySA-OH led to an increase in d3-
deoxySO-OH (I + II), and conversely, adding d3-deoxySO-OH 
increased the levels of d3-deoxySA-OH, indicating that this 
reaction is reversible (Fig. 4B). In contrast, d3-deoxySA-
2OH (sum of all four) was formed in the largest quantities 
after treatment with d3-deoxySA-OH, denoting that the di-
hydroxylated form is likely the direct product of d3-de-
oxySA-OH (Fig. 4B). However, 1-deoxySAdiene was only 
formed when supplementing the cells with d3-deoxySA or 
the different 1-deoxySO standards, but not with the frac-
tionated d3-deoxySA-OH or d3-deoxySO-OH (I + II). This 
indicates that 1-deoxySAdiene is formed directly down-
stream of 1-deoxySO (Fig. 4A, B).
In summary, all eight metabolites were formed down-
stream of 1-deoxySO, constituting three metabolic 
branches (Fig. 4C). It appears that 1-deoxySA-OH can also 
and Methods section. The three components that showed 
the greatest change over time (NRatio with NPvalue < 0.05) 
had odd-numbered masses, as would be expected for a d3-
labeled deoxysphingoid base (Fig. 2A).
In addition, the total-ion chromatogram was visually 
screened, leading to the identification of five additional 
d3-labeled 1-deoxySL metabolites (Fig. 2B). From the ac-
curate mass (5 ppm) and the constraint that the mole-
cule should contain a sulfur group originating from the 
o-phthalaldehyde/-mercaptoethanol derivatization, a 
specific chemical composition could be assigned to each of 
the eight metabolites. The identified compounds were hy-
droxyl-deoxySA (1-deoxySA-OH), hydroxyl-deoxySO I and 
II (1-deoxySO-OH; same exact mass, but different reten-
tion times), deoxysphingadiene (1-deoxySAdiene), and 
four isobaric peaks corresponding to dihydroxyl-deoxySA 
(1-deoxySA-2OH) (see Fig. 2B for putative structures).
The putative molecular formulas were further validated 
by comparing the retention times of the identified metabo-
lites. The addition of hydroxyl groups and DBs decrease 
hydrophobicity, meaning that these compounds would 
elute earlier from the column in reverse-phase LC (25, 26). 
Aligning the identified metabolites by their putative num-
ber of hydroxyl groups, one would predict an elution in the 
following order: 1-deoxySA-2OH (3 OHs), 1-deoxySO-OH 
(2OHs, 1 DB), 1-deoxySA-OH (2 OHs), 1-deoxySAdiene 
(1 OH, 2 DBs), 1-deoxySO (1 OH, 1 DB), 1-deoxySA (1 OH). 
This exactly reflects the observed elution order of the iden-
tified molecules (Fig. 2B).
All the newly identified downstream metabolites in-
creased over the 48 h of the chase (Fig. 2C). To assess 
whether the same downstream metabolites are also formed 
when 1-deoxySA is synthesized de novo, instead of being 
supplemented to the cells, we treated cells expressing the 
SPTLC1p.C133W HSAN1 mutant with -d3-labeled pal-
mitic acid and/or d4-alanine. SPTLC1p.C133W is the most 
common mutation in HSAN1 and cells expressing this mu-
tant show a significant increase in 1-deoxySL formation. 
The downstream metabolites were identified and quanti-
fied after acid/base hydrolysis according to the +3 mass dif-
ferences arising either from the -d3-palmitic acid or the 
d4-alanine, as well as the +6 mass differences resulting from 
the conjugation of both  labeled  substrates. All  identified 
1-deoxySL downstream metabolites were formed from the 
labeled palmitic acid and/or labeled alanine (supplemen-
tal Fig. S2).
The metabolic conversion of 1-deoxySLs is slow 
compared with canonical SLs
To compare the degradation of 1-deoxySLs and canoni-
cal SLs, we performed a 2 h pulse with either 1 M d3-de-
oxySA or 1 M d7-SA, followed by a 48 h chase. Labeled 
sphingoid and 1-deoxysphingoid bases were quantified by 
LC/MS after  acid/base hydrolysis. The d7-labeled  sphin-
goid bases disappeared almost completely during the 48 h 
chase, whereas the decrease in d3-deoxySLs (including all 
of the newly identified metabolites) was much less pro-
nounced (Fig. 3A). Also, while the same amount of d7-SA 
and d3-deoxySA was added, the concentration of d7-labeled 
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Fig. 2. Identification of eight novel 1-deoxySL metabolites that increase over time. A: Differential analysis using Sieve was performed for 
all metabolites between the 0 and 48 h time points of the chase in unsupplemented growth medium, after a 2 h pulse with d3-deoxySA. The 
volcano plot indicates all components identified with an m/z between 400 and 510, ratio >1, and P value <0.02. The P value and ratio shown 
are after normalization to the spiked internal standard d7-SA. The three black dots in the upper left indicate the metabolites with the greatest 
change in levels (these also had odd masses that could have a d3 label). B: Extracted ion chromatograms from the 48 h time point of the 
masses that passed the applied filtering criteria, as well as an additional mass (497.34838) identified by visual scanning of the total ion chro-
matogram. The structures were deduced after generating the chemical formula from the accurate mass (the conjugated OPA group is not 
shown for clarity). Note that the exact positions of the OH groups (except at C3) and the DBs along the carbon chain are unknown. The 
retention time of each metabolite on a C18 reverse phase column is indicated. The labeling of the individual 1-deoxySO-OH (I and II) and 
1-deoxySA-2OH (I, II, III, and IV) peaks refers to the different retention times. C: Levels of all of the newly identified d3-labeled metabolites 
increased over the 48 h chase period. Data are represented as mean ± SEM.
 at UZH Hauptbibliothek / Zentralbibliothek Zuerich, on M
arch 8, 2017
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/11/21/jlr.M072421.DC1
Supplemental Material can be found at:
66 Journal of Lipid Research Volume 58, 2017
after 24 h in the presence of the inhibitor, but instead con-
tinued to increase (supplemental Fig. S4B).
As HET0016 inhibits both CYP4A and CYP4F enzymes, 
we treated cells with all-trans retinoic acid (ATRA; 20 M), 
which preferentially induces the expression of CYP4F genes 
(32–34). ATRA treatment significantly increased all the 
d3-deoxySL downstream metabolites. In parallel, levels of 
d3-deoxySA were significantly lower with ATRA treatment, 
likely because of the increased downstream conversion 
(Fig. 5B).
Finally, to further analyze the role of specific CYP4A 
and CYP4F enzymes, we overexpressed mouse Cyp4a10  
or Cyp4f13 in HEK cells, and then treated cells with d3-
deoxySA. Overexpression of Cyp4a10 did not affect levels 
of the downstream metabolites, whereas overexpression of 
Cyp4f13 increased d3-deoxySA-OH and d3-deoxySA-2OH 
more than 2-fold as compared with wild-type cells (Fig. 6).
DISCUSSION
Current belief holds that 1-deoxySLs are metabolic 
“dead-end” products that cannot be degraded by the ca-
nonical SL catabolic pathway due to their missing C1 hy-
droxyl group. Here, we showed that, instead, 1-deoxySLs 
are metabolized by CYP4F enzymes.
We identified eight novel 1-deoxySL downstream me-
tabolites. The enzymes involved in the downstream metab-
olism of 1-deoxySLs appear not to have a high specificity, 
as nonnatural 1-deoxySO analogs were also metabolized 
(Fig. 3). In contrast to canonical SO, which bears a 4-5-
trans DB, the most abundant native 1-deoxySO contains a 
14,15-cis DB (20), suggesting that the DB in 1-deoxySO is 
introduced by a desaturase different to DES1. The identity 
of this enzyme has not yet been elucidated, but interest-
ingly, treating cells with synthetic 4,5-trans-1-deoxySO 
strongly stimulated the formation of 1-deoxySAdiene in 
comparison to treatment with the 14,15-cis-deoxySO 
be formed directly from 1-deoxySA, as levels were higher 
when cells were supplemented with d3-deoxySA than with 
1-deoxySO.
The downstream metabolism of 1-deoxySO is mediated by 
CYP4F enzymes
The observation that 1-deoxySLs are converted into sev-
eral mono- or poly-hydroxylated metabolites indicates a 
role of hydroxylases in this process. We hypothesized that 
CYP enzymes could be involved in the downstream metabo-
lism of 1-deoxySLs, as these enzymes are hydroxylases of 
both endogenous and exogenous substrates. In particular, 
we considered the CYP4A and CYP4F sub-families, which 
are involved in fatty acid hydroxylation, as their activity is 
enhanced by peroxisome proliferators like fibrates (27, 
28), and fenofibrate has been shown to lower 1-deoxySA 
and 14,15-cis-deoxySO levels in the plasma of dyslipid-
emic patients (29). Thus, we inferred that members of the 
CYP4A or CYP4F subfamilies could be involved in the 
downstream metabolism of 1-deoxySLs.
To test whether PPAR activation stimulates the down-
stream metabolism of 1-deoxySLs, we treated MEF cells 
with d3-deoxySA and fenofibrate (20 M) for 24 h and 
measured the levels of all d3-labeled 1-deoxySL metabolites 
(after acid/base hydrolysis). Fenofibrate increased the for-
mation of all labeled downstream metabolites, although 
only the increase in d3-deoxySA-OH, d3-deoxySO-OH II, 
and d3-deoxySAdiene was statistically significant (supple-
mental Fig. S3).
To further test the hypothesis that CYP4A or CYP4F en-
zymes are involved in 1-deoxySL metabolism, we supple-
mented cells for 24 h with d3-deoxySA and HET0016 (5 
M), a pan inhibitor of the CYP4A/CYP4F subfamilies (30, 
31). The presence of HET0016 significantly decreased the 
levels of all downstream metabolites in a dose-dependent 
manner (Fig. 5A, supplemental Fig. S4A). Furthermore, in 
pulse-chase experiments, d3-deoxySO no longer decreased 
Fig. 3. The metabolic conversion of 1-deoxySLs is slower than for canonical SLs. A: MEFs were treated with 
either 1 M d7-SA or d3-deoxySA for a 2 h pulse, followed by a chase period in unsupplemented growth me-
dium up to 48 h. The pulse medium was also collected and the d7-SA and d3-deoxySA content was measured. 
The total d3-labeled 1-deoxySLs (including the new metabolites) decreased over the chase period, although 
less than the d7-labeled canonical SLs did. While the total d7-labeled SLs were already much lower at time 
point 0, this was not a function of availability of the labeled lipids, as can be seen by the points at 2 h, which 
represent the total amount of d3-deoxySA and d7-SA in the pulse medium. B: MEFs were treated with a 2 h 
pulse of d3-deoxySA, followed by a chase period up to 8 days in unsupplemented growth medium. All of the 
d3-deoxySL metabolites increased until 4–6 days, and then drastically decreased by the final time point at 8 
days. Data are represented as mean ± SEM.
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detoxification/elimination pathway that typically involves 
CYP enzymes (37). Furthermore, compared with canoni-
cal SL catabolism, which occurs within minutes to hours, 
the conversion of 1-deoxySLs is slow and takes place over 
several days, which is also true of the detoxification pro-
cess. Detoxification usually occurs by two sequential steps 
referred to as phase I and phase II. In phase I, CYP enzymes 
isomer. This indicates that the same enzyme that intro-
duces the 14,15-cis DB in 1-deoxySA is also responsible for 
forming 1-deoxySAdiene from 4,5-trans-deoxySO. Of 
note, sphingadiene, a fairly abundant canonical C18-SL, 
also contains both a 4,5-trans and a 14,15-cis DB (35, 36).
The pathways downstream of 1-deoxySO appear to 
be highly branched and could be part of a cellular 
Fig. 4. All identified 1-deoxySL metabolites are produced downstream of 1-deoxySO and form a branched pathway. A: MEF cells were 
treated with d3-deoxySA, 14,15-cis-1-deoxySO, 14,15-trans-1-deoxySO, and 4,5-trans-1-deoxySO for 48 h (indicated along the x axis) and the 
resulting 1-deoxySL downstream metabolites were measured by LC/MS (d3-labeled for the d3-deoxySA treated condition and unlabeled for 
the other conditions; indicated by the different patterns). All metabolites were significantly increased compared with untreated controls 
upon treatment with any of the 1-deoxySO isomers. Statistical significance was calculated for individual metabolites arising from each treat-
ment versus untreated controls using the Student’s t-test. B: MEF cells were treated with isolated d3-deoxySA, d3-deoxySA-OH, and d3- 
deoxySO-OH (a mix of both I and II; indicated along the x axis) for 48 h, and the resulting downstream d3-labeled 1-deoxySL metabolites 
were measured by LC/MS (indicated by the different patterns). The amounts of each downstream metabolite produced from the different 
treatments were compared in pairs and significance was calculated using the Student’s t-test. C: Proposed metabolic pathway order. All bars 
represent averages ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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tabolites might be better possible in urine of HSAN1 pa-
tients, which would be expected to contain a significant 
concentration of these 1-deoxySL metabolites. Unfortu-
nately, urine from HSAN1 patients was not available at this 
time.
With regard to the potential role of CYP enzymes in this 
process, we specifically focused on the CYP4A and CYP4F 
subfamilies, which are known to be fatty acid hydroxylases 
and are moderately-to-highly expressed in MEF cells (43). 
The activity of CYP4A and CYP4F enzymes can be enhanced 
by peroxisome proliferators like fibrates (27, 28), and feno-
fibrate has been shown to lower 1-deoxySA and 14,15-cis-
deoxySO levels in the plasma of dyslipidemic patients (29). 
Thus, we inferred that CYP4A or CYP4F could potentially 
be involved in the downstream metabolism of 1-deoxySLs. 
However, while fibrates strongly induce CYP4A expression, 
they regulate CYP4F enzymes in an isoform-, tissue-, and 
species-specific manner, which could explain why fenofi-
brate had a weaker effect in MEFs compared with ATRA 
typically hydroxylate compounds to increase polarity; 
whereas in phase II, hydrophilic moieties like glucuronic 
acid  or  sulfate  esters  are  conjugated  to  further  increase 
water solubility (37). The 1-deoxySLs have been shown to 
be cytotoxic in a variety of cell types (5, 38–40), including 
cultured primary chicken dorsal root ganglia neurons (4) 
and pancreatic -cells (15), as well as to produce a neuro-
toxic phenotype in vivo (41, 42). Therefore, it is feasible 
that hydroxylation is a physiological way to prevent the 
toxic accumulation of these lipids. Initial attempts to iden-
tify glucuronidated or sulfonated 1-deoxySL downstream 
products were not successful, which may be due to low 
abundance and/or the quick elimination of these metabo-
lites. However, it is likely that this metabolic conversion 
is the reason we see the decline in all of the metabolites 
after 4 days, and that these glucuronidated or sulfonated 
products make up the remaining missing d3 label not 
accounted for by the newly identified metabolites. In the 
future, identification of glucuronidated or sulfonated me-
Fig. 5. Inhibition of CYP4F enzymes decreases the formation of the downstream d3-deoxySL metabolites, 
while induction of these enzymes increases their levels. Cells were treated with d3-deoxySA (1 M) and either 
the inhibitor HET0016 (5 M) or ATRA (20 M) for 24 h, after which the d3-deoxySLs were extracted and 
quantified by LC/MS. A: While the differences in d3-deoxySA and d3-deoxySO were not significant between 
controls and HET0016 treatment, the downstream d3-deoxySL metabolites were significantly decreased in 
the presence of the inhibitor. B: The d3-deoxySA was significantly lower in the ATRA-treated cells, while the 
downstream metabolites were all significantly and drastically increased. Statistical significance of the differ-
ences between untreated and treated cells was calculated using the Student’s t-test. Bars represent averages ± 
SEM. *P < 0.05, **P < 0.01; n.s., not significant. See also supplemental Figs. S3, S4.
Fig. 6. Levels of d3-deoxySA-OH and d3-deoxySA-
2OH significantly increase upon overexpression of 
Cyp4f13. HEK WT cells or HEK cells overexpressing 
either mouse Cyp4a10 or Cyp4f`13 were treated with 
d3-deoxySA for 48 h, and the d3-labeled 1-deoxySL 
downstream metabolites  were  measured  by  LC/MS. 
Levels of d3-deoxySA-OH (A) and d3-deoxySA-2OH 
(B) were significantly higher in Cyp4f13-overexpress-
ing cells. Levels of d3-deoxySO-OH (C) did not differ 
between the three cell lines. The sum of all four d3-
deoxySA-2OH peaks and both d3-deoxySO-OH peaks 
is shown. D: Western blot of CYP4F13 and CYP4A10 
expression. Bars represent averages ± SEM. Statistical 
significance was calculated using one-way ANOVA fol-
lowed by Bonferroni correction. **P < 0.01, ***P < 
0.001; n.s., not significant.
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In conclusion, neurotoxic and -cell toxic 1-deoxySLs 
are not catabolized by the canonical SL pathway, but by 
several hydroxylation and desaturation reactions that ap-
pear to be primarily mediated by CYP4F enzymes. In-
creased 1-deoxySA and 1-deoxySO levels in patients with 
MetS and T2D might therefore be explained by a down-
regulation of these enzymes. Consequently, induction of 
these enzymes could be a new therapeutic strategy in T2D, 
DSN, and HSAN1.
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(supplemental Fig. S3) (44–46). On the other hand, ATRA 
has been shown to be a strong inducer of CYP4Fs (32, 33), 
while it suppressed expression of CYP4A11 (34). Upon 
treatment with ATRA, we observed a more than 2-fold in-
crease in the downstream metabolites, suggesting that 
CYP4F rather than CYP4A enzymes are involved. This is fur-
ther supported by our finding that overexpression of 
Cyp4f13, but not of Cyp4a10, increased the production of 
two of the downstream metabolites in HEK293 cells. Pan 
inhibition of CYP4A/CYP4F enzymes prevented the down-
stream metabolism of 1-deoxySO.
Interestingly, CYP4A and CYP4F genes are differen-
tially regulated by conditions that increase the flux of 
free fatty acids, such as fasting (47), high-fat diet (48), 
or T2D (49). CYP4A expression is increased under these 
conditions, whereas CYP4F expression is decreased. A 
60- to 700-fold increase in mouse Cyp4a mRNA was ob-
served during fasting (50), while Cyp4f14 was found to 
be highly and significantly downregulated under these 
conditions (51). In mice on a high-fat diet, Cyp4a mRNA 
was increased 2.5- to 100-fold, while Cyp4f genes were 
downregulated by 20–80% (28). Preliminary data from 
Hardwick et al. (52) suggest that Cyp4f genes are also 
downregulated in an ob/ob mouse model of fatty liver 
disease. The downregulation of CYP4F enzymes in meta-
bolic conditions has interesting implications, as it sug-
gests that reduced degradation rather than increased 
formation is the reason for the elevated 1-deoxySL levels 
seen in MetS and T2D.
CYP4F enzymes have been shown to mediate the degra-
dation of fingolimod (FTY720), an S1P analog used in 
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